Inhibition of glucometabolism by a novel dehydroabielylamine derivative,DHAA-urea,in human hepatoma HepG2 cells
- VernacularTitle:脱氢枞胺衍生物DHAA-urea对人肝癌HepG2细胞糖代谢的抑制作用
- Author:
Jianxiang XIE
;
Ling HE
;
Luyong ZHANG
;
Xiaoping RAO
;
Zhanqian SONG
- Publication Type:Journal Article
- Keywords:
dehydroabietylamine derivatives;
glucolysis;
adenosine triphosphate;
HepG2 human hepatocellular carcinoma cells;
glycometabolism
- From:
Journal of China Pharmaceutical University
2010;41(2):160-165
- CountryChina
- Language:Chinese
-
Abstract:
The effects of DHAA-urea,a novel dehydroabietylamine(DHAA) derivatives,on cell viability and glucose metabolism,in hypoxia and normoxia human hepatoma HepG2 cells were investigated.Hypoxia cells were achieved using DMEM containing high concentration of glucose without serum and pre-incubating of CoCl_2 (final concentration 150 μmol/L) for 24 h.The antiproliferation effect of DHAA-urea was measured by colorimetric MTT assay.The cellular ATP concentration,the lactate dehydrogenase(LDH) and glucose-6-phosphate dehydro genase (G6PD) activity were detected by their kits.It was shown that DHAA-urea markedly inhibited cell viability,cellular ATP level,LDH and G6PD activity in either aerobic or anaerobic circumstance in a dose-and time dependent manner.This suggested that DHAA-urea possibly inhibited HepG2 cells growth via the inhibition of glucolysis and glucolysis-dependent ATP depletion.DHAA-urea could be a promising candidate in the development of a novel class of agents used for human hepatocellular carcinoma.
